$VCEL
Vericel Corp Stock $vcel

$vcel Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000162828017011022 Filed on November 07, 2017

Income Statement

Concept	2017 Q4	2017 Q3	2016 Q4
Revenue	$23.35M	$14.26M	$23.35M
YoY Change	0.0%	30.48%	51.43%
Cost Of Revenue	$8.390M	$7.186M	$7.590M
YoY Change	10.54%	4.81%	4.98%
Gross Profit	$14.96M	$7.074M	$14.96M
YoY Change	0.0%	73.68%	82.65%
Gross Profit Margin	64.07%	49.61%	64.07%
Selling, General & Admin	$10.18M	$8.186M	$7.930M
YoY Change	28.37%	16.78%	38.15%
% of Gross Profit	68.04%	115.72%	53.0%
Research & Development	$3.590M	$2.919M	$4.260M
YoY Change	-15.73%	-15.22%	-42.43%
% of Gross Profit	24.0%	41.26%	28.47%
Depreciation & Amortization	$420.0K	$410.0K	$500.0K
YoY Change	-16.0%	-12.77%	21.95%
% of Gross Profit	2.81%	5.8%	3.34%
Operating Expenses	$13.77M	$11.11M	$12.18M
YoY Change	13.05%	6.24%	-7.38%
Operating Profit	$1.191M	-$4.031M	$1.191M
YoY Change	0.0%	-36.82%	-124.03%
Interest Expense	$50.00K	$317.0K	-$310.0K
YoY Change	-116.13%	268.6%
% of Operating Profit	4.2%		-26.03%
Other Income/Expense, Net	-$100.0K	-$1.376M	$0.00
YoY Change		366.44%	-100.0%
Pretax Income	$290.0K	-$5.410M	-$6.200M
YoY Change	-104.68%	-19.01%	26.27%
Income Tax	$0.00
% Of Pretax Income	0.0%
Net Earnings	$287.0K	-$5.407M	$287.0K
YoY Change	0.0%	-19.0%	-105.85%
Net Earnings / Revenue	1.23%	-37.92%	1.23%
Basic Earnings Per Share
Diluted Earnings Per Share	$8.269K	-$160.7K	-$254.7K
COMMON SHARES
Basic Shares Outstanding	34.91M shares	32.82M shares	24.11M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q4	2017 Q3	2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$26.90M	$15.50M	$23.00M
YoY Change	16.96%	74.16%	57.53%
Cash & Equivalents	$26.86M	$15.50M	$22.98M
Short-Term Investments
Other Short-Term Assets	$1.581M	$1.366M	$1.164M
YoY Change	35.82%	84.35%	150.86%
Inventory	$3.793M	$4.049M	$3.488M
Prepaid Expenses
Receivables	$18.27M	$15.43M	$17.09M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$50.51M	$36.31M	$44.72M
YoY Change	12.93%	72.1%	63.56%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.071M	$3.967M	$3.875M
YoY Change	5.06%	-5.88%	-4.3%
Goodwill
YoY Change
Intangibles			$0.00
YoY Change			-100.0%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$4.071M	$3.967M	$3.875M
YoY Change	5.06%	-42.7%	-44.37%
TOTAL ASSETS
Total Short-Term Assets	$50.51M	$36.31M	$44.72M
Total Long-Term Assets	$4.071M	$3.967M	$3.875M
Total Assets	$54.58M	$40.28M	$48.60M
YoY Change	12.3%	43.74%	41.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.552M	$5.972M	$6.535M
YoY Change	-15.04%	9.24%	-13.88%
Accrued Expenses	$5.573M	$379.0K	$4.523M
YoY Change	23.21%	1479.17%	25.53%
Deferred Revenue	$420.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$400.0K	$2.600M	$800.0K
YoY Change	-50.0%
Total Short-Term Liabilities	$13.09M	$14.53M	$12.85M
YoY Change	1.84%	-5.42%	6.15%
LONG-TERM LIABILITIES
Long-Term Debt	$16.89M	$7.400M	$9.318M
YoY Change	81.24%	17519.05%	13023.94%
Other Long-Term Liabilities	$2.100M	$0.00	$32.00K
YoY Change	6462.5%	-100.0%
Total Long-Term Liabilities	$2.059M	$7.400M	$1.687M
YoY Change	22.05%	17519.05%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.09M	$14.53M	$12.85M
Total Long-Term Liabilities	$2.059M	$7.400M	$1.687M
Total Liabilities	$32.04M	$23.54M	$23.89M
YoY Change	34.1%	41.57%	96.16%
SHAREHOLDERS EQUITY
Retained Earnings	-$360.9M	-$361.2M	-$343.6M
YoY Change	5.03%	7.05%	6.04%
Common Stock	$383.0M	$377.7M	$329.7M
YoY Change	16.17%	21.76%	7.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)			$0.00
YoY Change			-100.0%
Treasury Stock Shares			0.000 shares
Shareholders Equity	$22.54M	$16.74M	$24.71M
YoY Change
Total Liabilities & Shareholders Equity	$54.58M	$40.28M	$48.60M
YoY Change	12.3%	43.74%	41.65%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2016 Q4
OPERATING ACTIVITIES
Net Income	$287.0K	-$5.407M	$287.0K
YoY Change	0.0%	-19.0%	-105.85%
Depreciation, Depletion And Amortization	$420.0K	$410.0K	$500.0K
YoY Change	-16.0%	-12.77%	21.95%
Cash From Operating Activities	$840.0K	-$5.240M	-$9.310M
YoY Change	-109.02%	25.36%	130.45%
INVESTING ACTIVITIES
Capital Expenditures	-$720.0K	-$520.0K	-$110.0K
YoY Change	554.55%	116.67%	10.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00		$0.00
YoY Change
Cash From Investing Activities	-$720.0K	-$520.0K	-$110.0K
YoY Change	554.55%	57.58%	22.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$18.00M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	11.28M	7.190M	23.50M
YoY Change	-52.0%	101.97%
NET CHANGE
Cash From Operating Activities	840.0K	-5.240M	-9.310M
Cash From Investing Activities	-720.0K	-520.0K	-110.0K
Cash From Financing Activities	11.28M	7.190M	23.50M
Net Change In Cash	11.40M	1.430M	14.08M
YoY Change	-19.03%	-250.53%	-440.92%
FREE CASH FLOW
Cash From Operating Activities	$840.0K	-$5.240M	-$9.310M
Capital Expenditures	-$720.0K	-$520.0K	-$110.0K
Free Cash Flow	$1.560M	-$4.720M	-$9.200M
YoY Change	-116.96%	19.8%	133.5%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	203000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-99000	USD
CY2017Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1060000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	512000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-17000	USD
	astm	Depreciation Depletionand Amortization Excluding Intangible Assets DepreciationDepletionandAmortizationExcludingIntangibleAssets	1200000	USD
CY2017Q3	astm	Depreciation Depletionand Amortization Excluding Intangible Assets DepreciationDepletionandAmortizationExcludingIntangibleAssets	400000	USD
	astm	Depreciation Depletionand Amortization Excluding Intangible Assets DepreciationDepletionandAmortizationExcludingIntangibleAssets	1200000	USD
	astm	Increase Decrease In Tenant Improvement Reimbursement IncreaseDecreaseInTenantImprovementReimbursement	898000	USD
	astm	Increase Decrease In Tenant Improvement Reimbursement IncreaseDecreaseInTenantImprovementReimbursement	89000	USD
CY2016Q4	astm	Lineof Creditand Term Loan Credit Agreement Current Netof Deferred Costs LineofCreditandTermLoanCreditAgreementCurrentNetofDeferredCosts	779000	USD
CY2017Q3	astm	Lineof Creditand Term Loan Credit Agreement Current Netof Deferred Costs LineofCreditandTermLoanCreditAgreementCurrentNetofDeferredCosts	2557000	USD
CY2017Q3	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDue	23361000	USD
CY2017Q3	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due Current OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueCurrent	1373000	USD
CY2017Q3	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due In Four Years OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueInFourYears	5021000	USD
CY2017Q3	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due In Three Years OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueInThreeYears	5049000	USD
CY2017Q3	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due In Two Years OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueInTwoYears	5519000	USD
CY2017Q3	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due Thereafter OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueThereafter	1307000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000887359
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	34907789	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Vericel Corp
CY2016Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4523000	USD
CY2017Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4514000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6535000	USD
CY2017Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	5972000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17093000	USD
CY2017Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15430000	USD
CY2016Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	2433000	USD
CY2017Q3	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	1608000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	422000	USD
CY2017Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	379000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7093000	USD
CY2017Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8279000	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	225000	USD
CY2017Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	226000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6500000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5400000	shares
CY2016Q4	us-gaap	Assets Assets	48598000	USD
CY2017Q3	us-gaap	Assets Assets	40278000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	44723000	USD
CY2017Q3	us-gaap	Assets Current AssetsCurrent	36311000	USD
CY2017Q3	us-gaap	Capital Lease Obligations CapitalLeaseObligations	43000	USD
CY2017Q3	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	11000	USD
CY2017Q3	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears		USD
CY2017Q3	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears		USD
CY2017Q3	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears		USD
CY2017Q3	us-gaap	Capital Leases Future Minimum Payments Due In Two And Three Years CapitalLeasesFutureMinimumPaymentsDueInTwoAndThreeYears	32000	USD
CY2017Q3	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter		USD
CY2015Q4	us-gaap	Cash Cash	14581000	USD
CY2016Q3	us-gaap	Cash Cash	8880000	USD
CY2016Q4	us-gaap	Cash Cash	22978000	USD
CY2017Q3	us-gaap	Cash Cash	15466000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5701000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-7512000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31595000	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34852000	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31595000	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34852000	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	329720000	USD
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	377711000	USD
CY2017Q1	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	0	shares
CY2016Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	6856000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	20716000	USD
CY2017Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	7186000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	21965000	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	190000	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2016Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	0	USD
CY2017Q3	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	110000	USD
CY2016Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	293000	USD
CY2017Q3	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	211000	USD
CY2017Q3	us-gaap	Deferred Rent Credit DeferredRentCredit	1000000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1687000	USD
CY2017Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1613000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	USD
CY2017Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	506000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1393000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1186000	USD
CY2016Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	757000	USD
CY2017Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1269000	USD
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.84
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.54
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-20000	USD
CY2016Q3	astm	Depreciation Depletionand Amortization Excluding Intangible Assets DepreciationDepletionandAmortizationExcludingIntangibleAssets	400000	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1668000	USD
CY2017Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2021000	USD
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2016Q3	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-6000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-17000	USD
CY2017Q3	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-6000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-20000	USD
CY2016Q3	us-gaap	Gross Profit GrossProfit	4073000	USD
	us-gaap	Gross Profit GrossProfit	17144000	USD
CY2017Q3	us-gaap	Gross Profit GrossProfit	7074000	USD
	us-gaap	Gross Profit GrossProfit	18609000	USD
CY2016Q1	us-gaap	Incentive From Lessor IncentiveFromLessor	2000000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2173000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1068000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-438000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-2000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-205000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-9000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2325000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	793000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	278000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	202000	USD
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	0	USD
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	129000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-3048000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-1663000	USD
CY2016Q3	us-gaap	Interest Expense InterestExpense	86000	USD
	us-gaap	Interest Expense InterestExpense	92000	USD
CY2017Q3	us-gaap	Interest Expense InterestExpense	317000	USD
	us-gaap	Interest Expense InterestExpense	878000	USD
	us-gaap	Interest Paid InterestPaid	73000	USD
	us-gaap	Interest Paid InterestPaid	691000	USD
CY2016Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	17000	USD
CY2017Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	43000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	3488000	USD
CY2017Q3	us-gaap	Inventory Net InventoryNet	4049000	USD
CY2016Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	3214000	USD
CY2017Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	3727000	USD
CY2016Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	257000	USD
CY2017Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	279000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	98000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	232000	USD
CY2016Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	7000	USD
CY2017Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	2000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	6000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	23890000	USD
CY2017Q3	us-gaap	Liabilities Liabilities	23541000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	48598000	USD
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40278000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12853000	USD
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	14528000	USD
CY2016Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9318000	USD
CY2017Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	7400000	USD
CY2017Q3	us-gaap	Minimum Lease Payments Sale Leaseback Transactions Due In Rolling After Year Five MinimumLeasePaymentsSaleLeasebackTransactionsDueInRollingAfterYearFive	5092000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6197000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7297000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1314000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-792000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10584000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14017000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-6675000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-13369000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-5407000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-17573000	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8606000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18960000	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5407000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17573000	USD
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-295000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-13000	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1376000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1398000	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	10453000	USD
	us-gaap	Operating Expenses OperatingExpenses	30500000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	11105000	USD
	us-gaap	Operating Expenses OperatingExpenses	34784000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6380000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13356000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4031000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-16175000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	20378000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	4546000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	4475000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	4473000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	4806000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	761000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	1317000	USD
CY2016Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1200000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	3600000	USD
CY2017Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1500000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4100000	USD
CY2016Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1164000	USD
CY2017Q3	us-gaap	Other Assets Current OtherAssetsCurrent	1366000	USD
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	259000	USD
CY2017Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	216000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	32000	USD
CY2017Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-10000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	244000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	300000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1314000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	792000	USD
	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	36000	USD
	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	486000	USD
CY2016Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1931000	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	5591000	USD
CY2017Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	469000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	7549000	USD
	us-gaap	Proceeds From Secured Lines Of Credit ProceedsFromSecuredLinesOfCredit	8400000	USD
	us-gaap	Proceeds From Secured Lines Of Credit ProceedsFromSecuredLinesOfCredit	0	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10968000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12246000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3875000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3967000	USD
CY2017Q3	us-gaap	Purchase Obligation PurchaseObligation	2940000	USD
CY2017Q3	us-gaap	Purchase Obligation Due After Fifth Year PurchaseObligationDueAfterFifthYear	546000	USD
CY2017Q3	us-gaap	Purchase Obligation Due In Fifth Year PurchaseObligationDueInFifthYear	546000	USD
CY2017Q3	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	546000	USD
CY2017Q3	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	45000	USD
CY2017Q3	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	681000	USD
CY2017Q3	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	576000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	28000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	252000	USD
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	2400000	USD
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	0	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3443000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11037000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2919000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9357000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-343591000	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-361164000	USD
CY2016Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	10929000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	37860000	USD
CY2017Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	14260000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	40574000	USD
CY2016Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7010000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	19463000	USD
CY2017Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8186000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	25427000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1973000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2053000	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Stock Issued1 StockIssued1	38389000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	24708000	USD
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	16737000	USD
CY2016Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	190000	USD
CY2017Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	190000	USD
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22744000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22678000	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	33667000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	32783000	shares
	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements included herein have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC).  The preparation of condensed consolidated financial statements in conformity with generally accepted accounting principles in the United States of America (U.S. GAAP) requires management to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations. The financial statements reflect, in the opinion of management, all adjustments (consisting only of normal, recurring adjustments) necessary to state fairly the financial position and results of operations as of and for the periods indicated.  The results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, are not necessarily indicative of the results to be expected for the full year or for any other period. The </font><font style="font-family:inherit;font-size:10pt;">September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> condensed consolidated balance sheet data was derived from the Company’s audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, as filed with the SEC on March 13, 2017 (Annual Report).</font></div></div>
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vericel Corporation, a Michigan corporation (the Company, Vericel, we, us or our), was incorporated in March 1989 and began employee-based operations in 1991. On May 30, 2014, Vericel completed the acquisition of certain assets and assumed certain liabilities of Sanofi, a French société anonyme (Sanofi), including all of the outstanding equity interests of Genzyme Biosurgery ApS (Genzyme Denmark or the Danish subsidiary) (now known as Vericel Denmark ApS), a wholly-owned subsidiary of Sanofi, and over </font><font style="font-family:inherit;font-size:10pt;">250</font><font style="font-family:inherit;font-size:10pt;"> patent applications of Sanofi and certain of its subsidiaries for purposes of acquiring the portion of the cell therapy and regenerative medicine business (the CTRM Business), which researches, develops, manufactures, markets and sells the Carticel</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;">, MACI</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;">, and Epicel</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> products. The Company is a fully integrated, commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of innovative therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. Vericel has marketed products and developmental stage product candidates, and the Company’s goal is to become the leader in cell therapy and regenerative medicine by developing, manufacturing and marketing best-in-class therapies for patients with significant unmet medical needs. </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates its business primarily in the U.S. in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> reportable segment — the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#222222;">The accompanying consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business.  As of </font><font style="font-family:inherit;font-size:10pt;color:#222222;">September 30, 2017</font><font style="font-family:inherit;font-size:10pt;color:#222222;">, the Company has an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;color:#222222;">$361.2 million</font><font style="font-family:inherit;font-size:10pt;color:#222222;"> and had a net loss of </font><font style="font-family:inherit;font-size:10pt;color:#222222;">$5.4 million</font><font style="font-family:inherit;font-size:10pt;color:#222222;"> during the quarter ended </font><font style="font-family:inherit;font-size:10pt;color:#222222;">September 30, 2017</font><font style="font-family:inherit;font-size:10pt;color:#222222;">.  The Company had cash of </font><font style="font-family:inherit;font-size:10pt;color:#222222;">$15.5 million</font><font style="font-family:inherit;font-size:10pt;color:#222222;"> as of </font><font style="font-family:inherit;font-size:10pt;color:#222222;">September 30, 2017</font><font style="font-family:inherit;font-size:10pt;color:#222222;">.  The Company expects that existing cash together with its </font><font style="font-family:inherit;font-size:10pt;">term loan and revolving line of credit agreement with Silicon Valley Bank (SVB) and MidCap Financial Services (MidCap) (the</font><font style="font-family:inherit;font-size:10pt;color:#222222;"> SVB-MidCap facility), will be sufficient to support the Company's </font><font style="font-family:inherit;font-size:10pt;">current operations through at least twelve months following the filing of this Form 10-Q</font><font style="font-family:inherit;font-size:10pt;color:#222222;">.  In connection with the SVB-MidCap facility, </font><font style="font-family:inherit;font-size:10pt;">the Company must remain in compliance with minimum monthly net revenue covenants (determined in accordance with U.S. GAAP), measured on a trailing twelve month basis. </font><font style="font-family:inherit;font-size:10pt;color:#222222;">SVB and MidCap also have the ability to call debt based on material adverse change clauses which are subjectively determinable and result in a </font><font style="font-family:inherit;font-size:10pt;">subjective acceleration clause. </font><font style="font-family:inherit;font-size:10pt;color:#222222;">If the Company's cash requirements exceed its current expectations, or if it is not in compliance with the monthly net revenue covenants or the subjective acceleration clauses are triggered under the SVB-MidCap facility, then SVB may call the debt resulting in the Company immediately needing additional funds.  As of </font><font style="font-family:inherit;font-size:10pt;color:#222222;">September 30, 2017</font><font style="font-family:inherit;font-size:10pt;color:#222222;">, the Company was in compliance with the minimum revenue covenant set forth in the Second Loan Modification Agreement between the Company, SVB and MidCap. The Company may seek additional funding through debt or equity financings including the at-the-market sales agreement in place with </font><font style="font-family:inherit;font-size:10pt;">Cowen and Company, LLC</font><font style="font-family:inherit;font-size:10pt;color:#222222;">.  However, the Company may not be able to obtain financing on acceptable terms or at all. The terms of any financing may adversely affect the holdings or the rights of the Company's shareholders.  If the Company needs additional funds and is unable to obtain funding on a timely basis, the Company may need to significantly curtail its operations including its research and development programs in an effort to provide sufficient funds to continue its operations, which could adversely affect its business prospects.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-17-011022-index-headers.html	Edgar Link	pending
0001628280-17-011022-index.html	Edgar Link	pending
0001628280-17-011022.txt	Edgar Link	pending
0001628280-17-011022-xbrl.zip	Edgar Link	pending
astm-20170930.xml	Edgar Link	completed
astm-20170930.xsd	Edgar Link	pending
astm-20170930_cal.xml	Edgar Link	unprocessable
astm-20170930_def.xml	Edgar Link	unprocessable
astm-20170930_lab.xml	Edgar Link	unprocessable
astm-20170930_pre.xml	Edgar Link	unprocessable
ex104-amendment1ictagreeme.htm	Edgar Link	pending
ex105-amendment2ictagreeme.htm	Edgar Link	pending
ex106-sidelettertoamendmen.htm	Edgar Link	pending
ex107-sidelettertoamendent.htm	Edgar Link	pending
ex108amendment1toorsiniagr.htm	Edgar Link	pending
ex311q32017-ceocertificati.htm	Edgar Link	pending
ex312q32017cfocertification.htm	Edgar Link	pending
ex321q32017-ceosoxcertific.htm	Edgar Link	pending
ex322q32017-cfosoxcertific.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vericel9301710q.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VCEL
Vericel Corp Stock $vcel

2017 Q4 Form 10-Q Financial Statement

#000162828017011022 Filed on November 07, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCEL Vericel Corp Stock $vcel

2017 Q4 Form 10-Q Financial Statement

#000162828017011022 Filed on November 07, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCEL
Vericel Corp Stock $vcel